Arena and Vivus’ approval of their obesity drugs — the first such approved in 13 years — have sent shockwaves throughout the industry. With Orexigen’s drug on the way, these have the potential to dramatically alter an entire sub-sector once left for dead. Still, despite positive data and FDA support, these drugs did not reach approval phase without several speed bumps along the way. And more questions are yet to come.
Millions of Americans suffer from sleep apnea, a disorder in which the patient repeatedly stops breathing during sleep.
A new study from the Scripps Research Institute has shown that the molecular mechanism that causes drug addiction is the same mechanism that drives people to compulsively eat.
GI Dynamics has received European CE mark approval to commercialize a non-surgical device for the management of obesity and Type 2 diabetes.
The race for an anti-obesity drug intensified Wednesday with the latest mid-stage trial data from Orexigen Therapeutics.
The Our Resolution movement is focused around the discovery that gastric bypass surgery resolves diabetes in approximately 77 percent of morbidly obese patients.
VIVUS, a pharmaceutical company specializing in products to treat sexual function, announced that their experimental obesity drug Qnexa was shown to improve blood sugar control in patients with type 2 diabetes.
Pharmaceutical company VIVUS has initiated an open label safety study of the investigational drug avanafil in males with erectile dysfunction.
Copyright © 2024 | WordPress Theme by MH Themes